Patients were randomly assigned 1:1 to receive either axitinib 5 mg orally twice daily or matching placebo, both combined with octreotide long-acting release 30 mg, in an international study.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/axitinib-boosts-neuroendocrine-tumor-objective-response-rate-2026a10008jd?src=rss
Author :
Publish date : 2026-03-20 11:17:00
Copyright for syndicated content belongs to the linked Source.
